BioNTech receives FDA Orphan Drug Designation for BNT327 in small cell lung cancer

BioNTech/BNT327

The FDA granted Orphan Drug Designation to BNT327 for small cell lung cancer treatment in June 2025. This designation provides regulatory incentives including extended market exclusivity and exemptions from certain fees, acknowledging the unmet need in this aggressive cancer type.